AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36626020 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise group (SEG) performing twice weekly moderate- to high-intensity training
Number of subjects: 63
Study 36626020 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) following national physical activity guidelines of ≥30-min moderate physical activity ≥5 days/week
Number of subjects: 63
Study 36626107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment initiated according to country-specific prescribing information, per physician discretion as part of routine care.
Number of subjects: 1000
Study 36626107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 1000
Study 36626172 — intervention group
Group type: EXPERIMENTAL
Intervention: Texas Sprouts intervention (school-based gardening, nutrition, and cooking intervention)
Number of subjects: 695
Study 36626172 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed intervention)
Number of subjects: 695
Study 36626193 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES)
Number of subjects: 282
Study 36626198 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers analyzed in urine and blood samples before the start of radiotherapy and at weeks 4, 12, and 48 of irradiation.
Number of subjects: 0
Study 36626198 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital telemonitoring platform Cureety for monitoring symptoms and quality of life.
Number of subjects: 0
Study 36626198 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm processing patient-reported information on symptoms and adverse events.
Number of subjects: 0
Study 36626198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year follow-up after treatment.
Number of subjects: 0
Study 36626409 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up (telephone and/or video assessment)
Number of subjects: 15358
Study 36626409 — intervention group
Group type: COMPARATOR
Intervention: In-person follow-up
Number of subjects: 15358
Study 36626409 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up (pooled mean from nonrandomized studies)
Number of subjects: 15358
Study 36626583 — intervention group
Group type: EXPERIMENTAL
Intervention: Pola-R-CHP (polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin, and prednisone)
Number of subjects: 281
Study 36626583 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 281
Study 36626583 — intervention group
Group type: EXPERIMENTAL
Intervention: Pola-R-CHP
Number of subjects: 281
Study 36626583 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 281
Study 36626675 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 0
Study 36626675 — intervention group
Group type: COMPARATOR
Intervention: Brisk walking
Number of subjects: 0
Study 36626696 — intervention group
Group type: COMPARATOR
Intervention: Digital breast tomosynthesis (DBT) alone
Number of subjects: 6179
Study 36626696 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT combined with technologist-performed handheld screening ultrasound (US)
Number of subjects: 6179
Study 36626696 — intervention group
Group type: EXPERIMENTAL
Intervention: US screening after DBT
Number of subjects: 6179
Study 36626956 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintervention after PMEG
Number of subjects: 170
Study 36626956 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintervention (early within 1 week)
Number of subjects: 170
Study 36626956 — intervention group
Group type: COMPARATOR
Intervention: No reintervention
Number of subjects: 170
Study 36626956 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintervention (overall)
Number of subjects: 170
Study 36627013 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkylating agent-based regimen
Number of subjects: 88
Study 36627013 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Number of subjects: 88
Study 36627013 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkylating agent-based regimen with POI without HRT
Number of subjects: 88
Study 36627013 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 36627145 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenously every 3 weeks
Number of subjects: 936
Study 36627145 — intervention group
Group type: COMPARATOR
Intervention: Bellmunt Risk Score
Number of subjects: 936
Study 36627145 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic model
Number of subjects: 936
Study 36627154 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy (CTE)
Number of subjects: 0
Study 36627156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful SensoriMotor Therapy (MiSMT) combined with transcranial direct current stimulation (tDCS)
Number of subjects: 8
Study 36627157 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic adherence monitoring (EAM) technologies
Number of subjects: 80
Study 36627157 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital pill system (ID-capsule manufactured by etectRX, named My/Treatment/Pill)
Number of subjects: 80
Study 36627157 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 80
Study 36627172 — intervention group
Group type: EXPERIMENTAL
Intervention: Swept-source wide-field optical coherence tomography angiography (OCTA) for choriocapillaris assessment
Number of subjects: 56
Study 36627172 — intervention group
Group type: EXPERIMENTAL
Intervention: Swept-source wide-field optical coherence tomography angiography (OCTA) for choroidal assessment
Number of subjects: 56
Study 36627206 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained longitudinal data analysis with natural cubic splines
Number of subjects: 0
Study 36627206 — intervention group
Group type: COMPARATOR
Intervention: Mixed model repeated measures (MMRM)
Number of subjects: 0
Study 36627253 — intervention group
Group type: EXPERIMENTAL
Intervention: Early closure (7-12 days)
Number of subjects: 36
Study 36627253 — intervention group
Group type: COMPARATOR
Intervention: Late closure (≥8 weeks)
Number of subjects: 36
Study 36627285 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with Adriamycin and cyclophosphamide (AC)
Number of subjects: 217
Study 36627285 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapies and/or additional chemotherapy post-NACT
Number of subjects: 217
Study 36627285 — intervention group
Group type: COMPARATOR
Intervention: Pre-NACT tumors molecular subtype
Number of subjects: 217
Study 36627602 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dietary sweetness exposure
Number of subjects: 180
Study 36627602 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dietary sweetness exposure
Number of subjects: 180
Study 36627602 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary sweetness exposure
Number of subjects: 180
Study 36627616 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring Distraction System (SDS)
Number of subjects: 28
Study 36627616 — intervention group
Group type: COMPARATOR
Intervention: One Way Self-Expanding Rod (OWSER)
Number of subjects: 28
Study 36627622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone beam computed tomography (CBCT) imaging features
Number of subjects: 84
Study 36627655 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 275
Study 36627655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 36627655 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily (sensitivity analysis)
Number of subjects: 275
Study 36627655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sensitivity analysis)
Number of subjects: 275
Study 36627711 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab Q4W
Number of subjects: 350
Study 36627711 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab Q8W
Number of subjects: 350
Study 36627711 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 350
Study 36628060 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern
Number of subjects: 0
Study 36628060 — intervention group
Group type: EXPERIMENTAL
Intervention: Less Healthy dietary pattern
Number of subjects: 0
Study 36628514 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-based functional MRI conducted 1 month posttrauma
Number of subjects: 130
Study 36628514 — intervention group
Group type: COMPARATOR
Intervention: Original brain-based biotypes of trauma resilience and psychopathology
Number of subjects: 130
Study 36628536 — intervention group
Group type: EXPERIMENTAL
Intervention: Posoleucel
Number of subjects: 58
Study 36628557 — intervention group
Group type: EXPERIMENTAL
Intervention: STANDING algorithm performed by interns
Number of subjects: 312
Study 36628557 — intervention group
Group type: EXPERIMENTAL
Intervention: STANDING algorithm performed by senior emergency physicians
Number of subjects: 312
Study 36628557 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between interns and senior EPs
Number of subjects: 312
Study 36628573 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatlimab plus nivolumab
Number of subjects: 0
Study 36628573 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab-nivolumab combination
Number of subjects: 0
Study 36628811 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers (n=118)
Number of subjects: 1052
Study 36628811 — intervention group
Group type: COMPARATOR
Intervention: Noncarriers (n=934)
Number of subjects: 1052
Study 36628811 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers (n=35, those desiring children postdiagnosis)
Number of subjects: 1052
Study 36628811 — intervention group
Group type: COMPARATOR
Intervention: Noncarriers (n=244, those desiring children postdiagnosis)
Number of subjects: 1052
Study 36628811 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers (n=81, those desiring children postdiagnosis)
Number of subjects: 1052
Study 36628811 — intervention group
Group type: COMPARATOR
Intervention: Noncarriers (n=674, those desiring children postdiagnosis)
Number of subjects: 1052
Study 36628879 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) involving mobile health 'cards' with electronic medical records and peer-delivered home-based services
Number of subjects: 33
Study 36628879 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR)
Number of subjects: 33
Study 36628879 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement and iterative discussions
Number of subjects: 33
Study 36628898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg once daily (2 weeks on/1 week off) plus sintilimab 200 mg Q3W
Number of subjects: 60
Study 36628898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg once daily (2 weeks on/1 week off) plus sintilimab 200 mg Q3W in mismatch repair-proficient mCRC
Number of subjects: 60
Study 36628969 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-enriched salt
Number of subjects: 0
Study 36628969 — intervention group
Group type: COMPARATOR
Intervention: Regular salt
Number of subjects: 0
Study 36628980 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical quality-of-care decisions scored against predetermined evidence-based criteria
Number of subjects: 219
Study 36628980 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct suspicion of PH
Number of subjects: 219
Study 36628980 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect identification of PH in non-PH cases
Number of subjects: 219
Study 36628980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordering of 2-dimensional echocardiography
Number of subjects: 219
Study 36628980 — intervention group
Group type: EXPERIMENTAL
Intervention: Presumptive diagnosis when 2-dimensional echocardiography was ordered in PH cases
Number of subjects: 219
Study 36628982 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter-ECG for up to 7 days in-hospital with systematic evaluation in a core cardiology laboratory
Number of subjects: 3465
Study 36628982 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic care
Number of subjects: 3465
Study 36628985 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 412
Study 36628985 — intervention group
Group type: COMPARATOR
Intervention: Typical American diet
Number of subjects: 412
Study 36629029 — intervention group
Group type: EXPERIMENTAL
Intervention: MC1R risk information (average or higher) provided to participants
Number of subjects: 447
Study 36629152 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally percutaneous access
Number of subjects: 318
Study 36629152 — intervention group
Group type: COMPARATOR
Intervention: Surgical cut-down femoral artery access
Number of subjects: 318
Study 36629972 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity during the COVID-19 pandemic (June-September 2020)
Number of subjects: 314
Study 36629972 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity during the COVID-19 pandemic (July-November 2021)
Number of subjects: 314
Study 36630120 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous sodium selenite (2000 μg/L prior to cardiopulmonary bypass, 2000 μg/L immediately postoperatively, and 1000 μg/L daily for up to 10 days)
Number of subjects: 1416
Study 36630120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1416
Study 36630140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab (LEB) + Topical Corticosteroids (TCS)
Number of subjects: 211
Study 36630140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Topical Corticosteroids (TCS)
Number of subjects: 211
Study 36630158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelight app for contactless measurement of vital signs (VS) using remote photoplethysmography (rPPG)
Number of subjects: 1950
Study 36630158 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care measurement of vital signs (automated sphygmomanometer for blood pressure; finger clip sensor for pulse rate and oxygen saturation; manual counting of respiratory rate)
Number of subjects: 1950
Study 36630158 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from patients and nurses using Lifelight via a questionnaire
Number of subjects: 1950
Study 36630158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness data of Lifelight compared with standard-of-care VS measurement
Number of subjects: 1950
Study 36630160 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call
Number of subjects: 110
Study 36630160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail
Number of subjects: 110
Study 36630160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail plus phone call
Number of subjects: 110
Study 36630160 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 110
Study 36630167 — intervention group
Group type: EXPERIMENTAL
Intervention: Opp mobile app intervention
Number of subjects: 381
Study 36630167 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 381
Study 36630213 — intervention group
Group type: EXPERIMENTAL
Intervention: Care transition intervention (CTI) - Discharge Information and Support for Patients receiving Outpatient care in the ED (DISPO ED)
Number of subjects: 24
Study 36630213 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination actions such as appointment scheduling and clinical health coaching recommendations
Number of subjects: 24
Study 36630213 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal support and empathy from the interventionist
Number of subjects: 24
Study 36630319 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual dexmedetomidine (BXCL501)
Number of subjects: 0
Study 36630319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36630406 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHD
Number of subjects: 0
Study 36630406 — intervention group
Group type: COMPARATOR
Intervention: Pre-filter CVVH
Number of subjects: 0
Study 36630619 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy
Number of subjects: 130
Study 36630619 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy
Number of subjects: 130
Study 36630629 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 36630953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic sighing
Number of subjects: 0
Study 36630953 — intervention group
Group type: EXPERIMENTAL
Intervention: Box breathing
Number of subjects: 0
Study 36630953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic hyperventilation with retention
Number of subjects: 0
Study 36630953 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness meditation
Number of subjects: 0
Study 36630958 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3463251 (GDF15 receptor agonist)
Number of subjects: 0
Study 36630958 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3463251 (single subcutaneous injection)
Number of subjects: 0
Study 36630958 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3463251 (12-week multiple ascending dose study)
Number of subjects: 0
Study 36630964 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) eligibility
Number of subjects: 200
Study 36631206 — intervention group
Group type: EXPERIMENTAL
Intervention: CITA
Number of subjects: 80
Study 36631206 — intervention group
Group type: COMPARATOR
Intervention: Device/lead extraction
Number of subjects: 80
Study 36631210 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-risk score
Number of subjects: 1121
Study 36631267 — intervention group
Group type: EXPERIMENTAL
Intervention: XXY (SCT) in humans
Number of subjects: 0
Study 36631267 — intervention group
Group type: EXPERIMENTAL
Intervention: XYY (SCT) in humans
Number of subjects: 0
Study 36631267 — intervention group
Group type: EXPERIMENTAL
Intervention: XXY (SCT) in mice
Number of subjects: 0
Study 36631267 — intervention group
Group type: EXPERIMENTAL
Intervention: XYY (SCT) in mice
Number of subjects: 0
Study 36631267 — intervention group
Group type: COMPARATOR
Intervention: XY controls in humans
Number of subjects: 0
Study 36631267 — intervention group
Group type: COMPARATOR
Intervention: XY controls in mice
Number of subjects: 0
Study 36631272 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral magnetic resonance-guided focused ultrasound subthalamotomy (FUS-STN)
Number of subjects: 32
Study 36631449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat (TAK924) given intravenously on days 1, 3, 5 of a 21-day cycle for 8 cycles at five dose levels (15 to 50 mg/m2)
Number of subjects: 0
Study 36631545 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT190 gene therapy (AAV2/S3-FRE1-GLAco) administered as a single intravenous dose in murine model and non-human primates (NHPs)
Number of subjects: 0
Study 36631545 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT190 gene therapy (AAV8-FLT190) in Fabry mice
Number of subjects: 0
Study 36631545 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT190 gene therapy in NHPs
Number of subjects: 0
Study 36631592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully closed-loop insulin delivery (no meal bolusing)
Number of subjects: 26
Study 36631687 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (LVSMD) infusion at 0.2 µg/kg/min over 24 hours
Number of subjects: 27
Study 36631687 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (LVSMD) infusion over 48 hours instead of 24 hours
Number of subjects: 27
Study 36631720 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec (5.6 U/kg) administered subcutaneously in the thigh
Number of subjects: 25
Study 36631720 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec (5.6 U/kg) administered subcutaneously in the abdomen
Number of subjects: 25
Study 36631720 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec (5.6 U/kg) administered subcutaneously in the upper arm
Number of subjects: 25
Study 36631725 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 + P
Number of subjects: 444
Study 36631725 — intervention group
Group type: COMPARATOR
Intervention: TCH + P
Number of subjects: 444
Study 36631767 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained NCMs (intervention)
Number of subjects: 30
Study 36631767 — intervention group
Group type: COMPARATOR
Intervention: Untrained NCMs (control)
Number of subjects: 30
Study 36631812 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-targeted peptide probe
Number of subjects: 0
Study 36631812 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT/CT imaging
Number of subjects: 0
Study 36631822 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Phallopexy (anchoring the penile skin dermis to Buck's fascia at the penile base at 3 and 9 o'clock points using PDS 5/0)
Number of subjects: 150
Study 36631822 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Complete dissection and excision of dartos fascia
Number of subjects: 150
Study 36631822 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Phallopexy after complete dissection and excision of dartos fascia
Number of subjects: 150
Study 36631821 — intervention group
Group type: EXPERIMENTAL
Intervention: New postpartum haemorrhage care bundle (E-MOTIVE)
Number of subjects: 45
Study 36631821 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed interventions (Education, Training, Modelling, Enablement, Persuasion, Environmental Restructuring)
Number of subjects: 45
Study 36631831 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 1804
Study 36631831 — intervention group
Group type: COMPARATOR
Intervention: Volatile agent
Number of subjects: 1804
Study 36631859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Decision Support System using two-dimensional video files of cardiac sweeps
Number of subjects: 0
Study 36631859 — intervention group
Group type: COMPARATOR
Intervention: Standard first-trimester fetal echocardiography (FE)
Number of subjects: 0
Study 36631869 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities for Healthy Living (CHL) intervention during intervention periods
Number of subjects: 1274
Study 36631869 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents who enrolled in PConnect
Number of subjects: 1274
Study 36631869 — intervention group
Group type: COMPARATOR
Intervention: Control periods
Number of subjects: 1274